NASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $58.88 -0.14 (-0.24%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Royalty Pharma Stock (NASDAQ:RPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Royalty Pharma alerts:Sign Up Key Stats Today's Range$58.90▼$59.7250-Day Range$52.07▼$59.0252-Week Range$34.08▼$59.72Volume627,096 shsAverage Volume3.60 million shsMarket Capitalization$33.90 billionP/E Ratio40.05Dividend Yield1.60%Price Target$56.57Consensus RatingBuy Company Overview Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines. The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors. Royalty Pharma’s portfolio spans multiple therapeutic areas and stages of product life cycles; revenues are derived from sales of underlying drugs in markets around the world. Its business model is positioned to provide liquidity to biopharma owners while assuming the commercial and regulatory risk associated with future product sales. Founded by Pablo Legorreta and headquartered in New York, Royalty Pharma completed a public listing on the Nasdaq under the ticker RPRX in 2020. The company operates globally, collecting royalties generated by product sales in multiple geographies and partnering with a wide range of industry participants. Pablo Legorreta, the company’s founder and long-time leader, has been a central figure in Royalty Pharma’s strategy of building a large, diversified portfolio of biopharma royalty assets.AI Generated. May Contain Errors. Read More Royalty Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreRPRX MarketRank™: Royalty Pharma scored higher than 73% of companies evaluated by MarketBeat, and ranked 257th out of 835 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingBuy Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Royalty Pharma is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth4.44% Earnings GrowthEarnings for Royalty Pharma are expected to grow by 4.44% in the coming year, from $5.18 to $5.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 40.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 40.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.84.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 10.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.66% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 2.98, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently increased by 11.77%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldRoyalty Pharma pays a meaningful dividend of 1.60%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has been increasing its dividend for 5 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 63.95%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 17.38% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. News and Social Media3.8 / 5News Sentiment1.05 News SentimentRoyalty Pharma has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Royalty Pharma this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,333,723.00 in company stock.Percentage Held by Insiders18.84% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RPRX Stock News HeadlinesRoyalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from NeurimmuneJuly 22 at 7:36 AM | markets.businessinsider.comRoyalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from NeurimmuneJuly 22 at 7:05 AM | globenewswire.comTwo paths to universal income. One already exists today.Robert Kiyosaki, author of Rich Dad Poor Dad, says there are two paths to Universal Basic Income - wait for Elon Musk's robots, or start collecting 10% a year right now from America's oil and gas infrastructure. He calls it the Patriot Income Plan - 42 automatic payouts a year with minimal enrollment requirements. Some participants report collecting $4,800 to $25,000 per month.July 24 at 1:00 AM | Freedom Financial (Ad)RPRX Stock Price PredictionJuly 20, 2026 | 247wallst.comRoyalty Pharma declares third quarter 2026 dividendJuly 17, 2026 | globenewswire.comRoyalty Pharma to announce second quarter 2026 financial results on August 5, 2026July 15, 2026 | globenewswire.comRoyalty Pharma (NASDAQ:RPRX) EVP Sells 9,099 Shares of StockJuly 3, 2026 | insidertrades.comMarshall Urist Sells 9,098 Shares of Royalty Pharma (NASDAQ:RPRX) StockJune 26, 2026 | insidertrades.comSee More Headlines RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $38.64 at the beginning of 2026. Since then, RPRX shares have increased by 52.7% and is now trading at $59.02. How were Royalty Pharma's earnings last quarter? Royalty Pharma PLC (NASDAQ:RPRX) announced its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.08. The biopharmaceutical company had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a trailing twelve-month return on equity of 29.25% and a net margin of 33.88%. Read the conference call transcript. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Top institutional investors of Royalty Pharma include Wedge Capital Management L L P NC (0.13%), Eastern Bank (0.12%), Handelsbanken Fonder AB (0.10%) and Cooper Investors PTY Ltd. (0.03%). Insiders that own company stock include Avara Management Ltd, Gregory Norden, Christopher Hite, Rory B Riggs, Terrance P Coyne, Marshall Urist and George W Lloyd. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Bristol Myers Squibb (BMY), Chevron (CVX), McKesson (MCK), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/06/2026Record date for 6/10 Dividend5/15/2026Ex-Dividend for 6/10 Dividend5/15/2026Dividend Payable6/10/2026Today7/24/2026Next Earnings (Estimated)8/05/2026Record date for 9/10 Dividend8/14/2026Ex-Dividend for 9/10 Dividend8/14/2026Dividend Payable9/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 RPRX's financial health is in the Green zone, according to TradeSmith. RPRX has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CIK1802768 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees80Year Founded1996Price Target and Rating Average Price Target for Royalty Pharma$56.57 High Price Target$66.00 Low Price Target$42.00 Potential Upside/Downside-3.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$1.47 Trailing P/E Ratio40.13 Forward P/E Ratio11.37 P/E Growth10.4Net Income$770.95 million Net Margins33.88% Pretax Margin55.63% Return on Equity29.25% Return on Assets14.71% Debt Debt-to-Equity Ratio0.86 Current Ratio2.66 Quick Ratio2.66 Sales & Book Value Annual Sales$2.38 billion Price / Sales14.26 Cash Flow$4.79 per share Price / Cash Flow12.29 Book Value$16.83 per share Price / Book3.50Miscellaneous Outstanding Shares575,830,000Free Float467,345,000Market Cap$33.91 billion OptionableOptionable Beta0.43 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:RPRX) was last updated on 7/24/2026 by MarketBeat.com Staff. From Our PartnersTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | SponsoredTwo paths to universal income. One already exists today.Robert Kiyosaki, author of Rich Dad Poor Dad, says there are two paths to Universal Basic Income - wait for El...Freedom Financial | SponsoredElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning s...Brownstone Research | SponsoredA Wall Street Veteran's Weekly Options Strategy ExplainedA former Merrill Lynch and Vanguard advisor spent 25 years watching one weekly options play generate consisten...Base Camp Trading | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredSam Altman backs small company that could save U.S. power gridA small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...Altimetry | SponsoredThe dollar in your pocket is not the firstThe dollar has already been reborn twice. In 1971, Nixon severed it from gold. In 1974, a secret deal with Sau...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
